Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wilkinson, PM; Antonopoulos, M; Lahousen, M; Lind, M; Kosmidis, P; EPO-INT-45 Study Group.
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.
Br J Cancer. 2006; 94(7):947-954 Doi: 10.1038/sj.bjc.6603004 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar


Co-Autor*innen der Med Uni Graz
Lahousen Manfred

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

This multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life (QOL) parameters in 182 anaemic (Hb< or = 12 g dl(-1)) ovarian cancer patients receiving platinum chemotherapy. Patients were randomised 2 : 1 to receive epoetin alfa 10,000-20 000 IU three times weekly plus best standard treatment (BST) or BST only. Main study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL. For the epoetin alfa group, mean Hb increased by 1.8 g dl(-1) by weeks 4-6 and was significantly increased from baseline through study end (P<0.001). The mean change in Hb from baseline was significantly (P<0.001) greater for epoetin alfa than BST patients at all post-baseline evaluations. Significantly fewer epoetin alfa than BST patients required transfusion(s) after the first 4 weeks of treatment (7.9 vs 30.5%; P<0.001). Also, significant (P< or = 0.04) differences favouring the epoetin alfa group over the BST group were found for all three median CLAS scores (Energy Level, Ability to Do Daily Activities, Overall QOL) and the median average CLAS score during chemotherapy. These findings support use of epoetin alfa to increase Hb levels, reduce transfusion use, and improve QOL in anaemic ovarian cancer patients receiving platinum chemotherapy.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use
Blood Transfusion -
Cisplatin - adverse effects Cisplatin - therapeutic use
Erythropoietin - therapeutic use
Female -
Hematinics - therapeutic use
Hemoglobins - analysis
Humans -
Middle Aged -
Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology
Quality of Life -
Recombinant Proteins -

Find related publications in this database (Keywords)
epoetin alfa
quality of life
© Med Uni Graz Impressum